The assessment of metabolites by 1 H MRS can provide information regarding glioma growth, and may be able to distinguish between different glioma models. Rat C6, 9 L/LacZ, F98 and RG2, and mouse GL261, cells were intracerebrally implanted into the respective rodents, and human U87 MG cells were implanted into athymic rats. Ethyl-nitrosourea induction was also used. Glioma metabolites [e.g. total choline (tCho), total creatine (tCr), N-acetylaspartate (NAA), lactate (Lac), glutamine (Gln), glutamate (Glu), aspartate (Asp), guanosine (Gua), mobile lipids and macromolecules (MMs)] were assessed from 1 H MRS using point-resolved spectroscopy (PRESS) [TE = 24 ms; TR = 2500 ms; variable pulse power and optimized relaxation delay (VAPOR) water suppression; 27-mL and 8-mL voxels in rats and mice, respectively] at 7 T. Alterations in metabolites (Totally Automatic Robust Quantitation in NMR, TARQUIN) in tumors were characterized by increases in lipids (Lip1.3: 8.8-54.5 mM for C6 and GL261) and decreases in NAA (1.3-2.0 mM for RG2, GL261 and C6) and tCr (0.8-4.0 mM for F98, RG2, GL261 and C6) in some models. F98, RG2, GL261 and C6 models all showed significantly decreased (p < 0.05) tCr, and RG2, GL261 and C6 models all exhibited significantly decreased (p < 0.05) NAA. The RG2 model showed significantly decreased (p < 0.05) Gln and Glu, the C6 model significantly decreased (p < 0.05) Asp, and the F98 and U87 models significantly decreased (p < 0.05) Gua, compared with controls. The GL261 model showed the greatest alterations in metabolites. 1 H MRS was able to differentiate the metabolic profiles in many of the seven rodent glioma models assessed. These models are considered to resemble certain characteristics of human glioblastomas, and this study may be helpful in selecting appropriate models.
INTRODUCTION
Gliomas represent 40% of all diagnosed primary central nervous system tumors. Among them, glioblastomas (GBMs) are the most malignant, with a very poor survival time of 15 months for any patient diagnosed with this grade IV brain tumor (1) . Because of this short window of time allowed for treatment, there is no room for mistaken diagnosis and glioma characteristics must be precisely and quickly assessed (2) . Important grading and identification criteria that can be used to precisely depict tumor behavior include cell proliferation (cellularity and mitotic activity), nuclear atypia, neovascularization and the presence of necrosis and/or apoptotic regions (3) . Grade II gliomas ('diffuse astrocytomas') and grade III gliomas ('anaplastic astrocytomas') differ only on the basis of the presence of mitotic activity, and this difference accounts for a dramatic decrease in 5-year survival for patients, from 47% to 29% (from grade II to III, respectively) (1). Grade IV gliomas ('GBM') are often characterized by large necrotic areas (3) and present a 5-year survival rate of 3% (1) .
These grading criteria, in particular, can be assessed in vivo using noninvasive MR techniques. The focus of this study was to use 1 H MRS to determine whether metabolic profiles could be employed to differentiate between diverse rodent glioma models. A knowledge of the amount of and changes in brain metabolites, which reflect processes such as cell proliferation (4) and cell death (5, 6) , may provide additional information for tumor grading. 1 H MRS has already been reported as an efficient technique for discriminating between brain lesions (7) (8) (9) and for following the response to treatments (10) . It possesses several advantages over biopsies, which represent the usual grading method in clinics. Biopsies have several limitations including sampling error, possible complications, invasiveness, limited sample size and patient discomfort. For instance, it has been found that at least 10% of biopsies do not provide any useful diagnostic information to the physician (11, 12) and, unfortunately there have been cases of patients dying as a result of biopsy procedures (11, 13) . 1 H MRS is a useful method for the assessment of the main brain metabolic biomarkers: N-acetylaspartate (NAA), total choline (tCho), total creatine (tCr), lactate (Lac) and mobile lipids. Rapidly growing tumors are known to present an increase in tCho levels [as a result of the increase in membrane synthesis during cell proliferation (4) ]. Any neuronal death will be translated into a decrease in NAA levels (5) , an important neuronal marker (14) . The level of tCr relates to the ADP/ATP energy cycle (15) , and is generally decreased in astrocytomas, compared with normal brain tissue (16, 17) . It is well known that neoplastic cells have an increased capacity for glycolytic metabolism (18) . Lac is an end product of glycolysis, and has been found to increase in rodent glioma models (18) . In addition, the presence of mobile lipids is recognized as a characteristic feature associated with malignant gliomas (4) , and this is thought to be caused by membrane breakdown during necrosis (6, 19) .
The first step was to obtain robust and reliable glioma models by intracerebral implantation of tumor cells (20) from different cell lines varying in their degree of malignancy (rat C6, 9 L/LacZ, F98 and RG2, mouse GL261 and human U87) to yield a range of gliomas from moderately aggressive (grade III) to GBM-like (grade IV). A chemically induced glioma model was also implemented following ethyl-nitrosourea (ENU) administration (21, 22) . Each of these cell implantation models is considered to be a reliable model of GBM (grade IV) (20, (23) (24) (25) with, however, slightly different malignancies [from diffusively invasive C6 (20) and GL261 (26) gliomas to the aggressive grade IV U87 model (25, 27) ]. The C6 cell line produces diffusively invasive astrocytomas (20) , has been found to show a great similarity to human glioma cells in the expression of genes mainly involved in tumor progression (28) , and the C6 model has been widely used as a GBM model for years (23) . 9 L/LacZ-originating tumors are aggressive and infiltrative, and possess the characteristics of human GBM (24) , notably its angiogenic behavior (29) . F98 gliomas are classified as anaplastic malignant tumors, show an infiltrative pattern of growth and also resemble human GBM (20) . The aggressive and invasive nature of RG2 tumors (20) mimics human high-grade gliomas by inducing important vascular alterations (30) , as does the highly tumorigenic GBM U87 MG cell line (25, 27) . GL261 cells give rise to rapidly growing, slightly invasive intracranial tumors in C57BL/6 mice (26). Finally, ENU induction gives rise to low-grade oligodendrogliomas and mixed variable-grade gliomas, with a tumor incidence approaching 100% (22) . By studying all of these glioma models, we hoped to show that 1 H MRS is a sufficiently sensitive technique to depict slight differences between some of these GBM models, and to demonstrate that 1 H MRS may be a useful additional tool for glioma grading.
METHODS

Cell culture
Primary rat neocortical astrocytes were kindly obtained from Dr Hensley's group at the Oklahoma Medical Research Foundation, OK, USA (31) . The murine GL261 cell line was kindly provided by Dr Safrany from the Frederic Joliot-Curie National Research Institute for Radiobiology and Radiohygiene, Budapest, Hungary (26) . The rat C6, 9 L/LacZ, F98 and RG2, and human U87, glioma cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). All cell lines were cultured at 37 C with 5% CO 2 in high-glucose Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (32, 33) (with the exception of human U87 cells which favored Eagle's minimal essential medium). Before implantation, the cells were briefly trypsinized, centrifuged and resuspended in Dulbecco's modified Eagle's medium or Eagle's minimal essential medium. Agarose (Sigma-Aldrich, St. Louis, MO) was added to the final suspension to obtain a 1% ultralowtemperature gelling agarose cell suspension (32) , which was kept in a sterile vial at 37 C until implantation.
Cell implantation
The animal study was conducted in compliance with the Oklahoma Medical Research Foundation Institutional Animal Care and Use Committee. The rat glioma cell implantation models were obtained as described previously by our group (34) . Briefly, 3-month-old male Fischer 344 rats (Harlan Inc., Indianapolis, IN, USA) were anesthetized and immobilized on a stereotaxic unit. A hole was drilled through the skull 2 mm anterior and 2 mm lateral to the bregma, on the right-hand side of the skull. Ten thousand cells of the desired cell line (C6, 9 L/LacZ, F98 or RG2), suspended in a 10-mL volume, were injected at a depth of 3 mm from the dura into the cerebral cortex, at a rate of 2 mL/min, followed by a waiting time of 2 min. Control injections of primary rat astrocytes were conducted in the same conditions. The human U87 glioma model was obtained by injecting 3-month-old male athymic rnu/rnu rats (Charles River Laboratories, Wilmington, MA, USA) with 100 000 U87 MG cells at a rate of 0.8 mL/min, followed by a waiting time of 5 min. Two-month-old C57BL/6 male mice were implanted with 2 Â 10 4 GL261 cells in a volume of 4 mL, 1 mm anterior and 2 mm lateral to the bregma, at a depth of 1.5 mm, using an injection rate of 0.6 mL/min. For rat and human glioma cell implantations, we usually used cells starting from their third passage, and did not exceed more than 30 passages. For the GL261 mouse glioma cell implantations, we did not use cells that had undergone more than 20 passages.
ENU induction
A 0.1 M solution of ENU was prepared in citric acid and phosphate buffer (pH 6) immediately before use. Pregnant Fischer 344 female rats were injected intravenously into the tail vein with an ENU suspension of 50 mg/kg at 21 days of pregnancy, as recommended by Kish et al. (21) . The offspring were delivered naturally and weaned at 22 days. Only males were selected for our study, and were kept under weekly observation for any sign of neurological or health problems.
MR experiments
Basic brain morphology and spectroscopy datasets were acquired for four rats implanted with primary astrocytes ('CTRL'), five C6-implanted animals ('C6'), four 9 L/LacZ-implanted rats ('9 L/LacZ'), four F98-implanted animals ('F98'), five RG2-injected rats ('RG2'), five U87 MG-implanted animals ('U87'), five GL261-injected mice ('GL261') and four male rats exposed transplacentally to ENU ('ENU'). Animals were imaged at the Oklahoma Medical Research Foundation Nuclear Magnetic Resonance Core Facility, using a 30-cm, horizontal bore, 7-T magnet (Bruker BioSpin MRI GmbH, Ettlingen, Germany) at day 7 after cell implantation, and then every third day for the orthotopic glioma models. Maximum tumor dimensions were reached at days 17-21 for C6, days 14-26 for RG2, days 15-35 for U87, days 36-47 for 9 L/LacZ, days 18-26 for F98 and days 23-35 for GL261. The rats bearing ENU-induced gliomas were imaged at 3 months of age and then every month.
Each animal was anesthetized (2% isoflurane at 0.7 L/min oxygen) and immobilized in an MR probe head first and in a prone position. A head surface coil was used to receive the induced MR signal. A quadrature volume coil was used for the transmission of all radiofrequency pulses (Bruker BioSpin MRI GmbH). After checking the correct positioning of the brain at the isocenter, morphological T 2 -weighted images of the whole cerebrum were acquired using a multi-slice RARE (rapid acquisition with relaxation enhancement) sequence. Twenty-four contiguous transverse slices, 1 mm thick, were taken at TR = 3000 ms and TE = 63 ms, in a field of view of 3.5 Â 3.5 cm 2 , for a total acquisition time of 13 min, and resulting in an approximate in-plane resolution of 140 mm. Mouse brain morphological images were acquired with a slice thickness of 0.5 mm and a field of view of 2 Â 2 cm 2 , for an approximate in-plane resolution of 80 mm. Spectra were acquired in a 3 Â 3 Â 3 mm 3 voxel (2 Â 2 Â 2 mm 3 in mice) centered on the cell implantation site and on its mirror location in the other hemisphere, using a PRESS (point-resolved spectroscopy) sequence with TE = 24 ms, TR = 2500 ms, 256 averages, a spectral width of 4006 Hz and a VAPOR (variable pulse power and optimized relaxation delay) (35) water suppression scheme, for a total acquisition time of 11 min. Adjustments of the firstand second-order shims were conducted beforehand using Fastmap (36) , until the width of the water peak at mid-height was less than 30 Hz.
Data analysis
Tumor volumes and doubling times (T d ) were determined from the T 2 -weighted images, as described previously by our group (34) . The latency time (number of days needed by the implanted cells to form a tumor of 10 mm 3 in size) and morphology of each glioma were also noted.
Initial processing (apodization with a line broadening factor of 5 and Fourier transformation) of the MRS data was performed using the 'Bruker TopSpin' tool available with Paravision software (PV4.0, Bruker BioSpin MRI GmbH). Each spectrum was then phase corrected, scaled in parts per million and calibrated on the water peak (4.78 ppm) using a Mathematica notebook written in-house (Mathematica 7.0, Wolfram Research, Champaign, IL, USA).
For the estimation of the absolute quantification of 1 H MRS metabolites, the Totally Automatic Robust Quantitation in NMR (TARQUIN) method [as more fully described by Reynolds et al. consists of the following: (i) preprocessing (removal of postacquisition residual water by Hankel singular value decomposition, automatic phasing); (ii) basis set simulation (quantum mechanical simulation of 1 H NMR signals from small molecules); and (iii) solution of a nonlinear least-squares fitting problem (modeling of the experimental data as a linear combination of modified basis signals and, following the adjustment of all segments, resimulation of the basis set and synthesis at the new frequencies) (37, 38) . The amplitudes of the metabolite signals were estimated to be expressed in absolute units by scaling the fitted signal amplitudes to the amplitude of an unsuppressed water resonance (obtained from an additional experiment), where the concentration of water is known for particular tissue types (37, 38) . The TARQUIN program was obtained at http://tarquin.sourceforge.net/. 1 H MRS sequence details (TE, pulse sequence, reference offset) and the spectrometer frequencies (sampling and transmitter frequencies) were confirmed prior to peak simulation. Peak metabolite concentration estimates were further normalized [in addition to the water concentration of 35.88 mol/L in brain tissue (38) ] to published rat brain tCr (creatine + phosphocreatine) levels of 7.5 mmol/kg wet weight, as reported by Cudalbu et al. (39) . The tCr signals and concentrations in control animals and contralateral 'normal' brain tissue were used as references to obtain the concentrations of other metabolites in glioma tissues in each model. The assignment of metabolites was based on published literature: for example, NAA was assigned at 2.02 ppm, tCr at 3.03 ppm, tCho at 3.22 ppm, Lac at 1.32 ppm, alanine (Ala) at 1.47 ppm, glutamine (Gln) at 2.12 ppm, glutamate (Glu) at 2.35 ppm, aspartate (Asp) at 2.79 ppm, taurine (Tau) at 3.42 ppm and myo-inositol (myo-Ins) at 3.53 ppm (40) . Mobile lipid peaks are usually absent from normal brain tissue, but are visible at 1.29 and 0.88 ppm in tumor tissue samples, and are associated with the fatty acyl proton groups CH 2 (predominantly saturated methylene hydrogens; Lip1.3 = Lip1.3a + Lip1.3b) and CH 3 (methyl hydrogens; Lip0.9), respectively (41) . It should be noted that the 1.3-ppm peak is a composite peak with contributions from both the Lac methyl and lipid methylene protons (42) . For some metabolites, concentrations were combined to reflect total levels {e.g. tCr included all creatine-containing compounds, tCho included all choline-containing compounds (glycerophosphocholine + phosphocholine), NAA = NAA + N-acetylaspartylglutamate (NAAG), and macromolecules (MMs) included all MM peaks [0.92 ppm (MM09), 1.21 ppm (MM12), 1.39 ppm (MM14), 1.67 ppm (MM17) and 2.04 ppm (MM20)] (40)}. The basis set simulation set included all of the metabolites listed above and, in addition, g-aminobutyric acid (GABA), glucose (Glc), scyllo-inositol (Scyllo), guanosine (Gua) and Lip2.0.
Statistical analysis
Statistical analysis of the data was conducted with Prism 5.01 (GraphPad software, LaJolla, CA, USA). Differences in estimated metabolite concentrations between groups were examined using two-tailed, unpaired, Student's t-tests with Welch's correction. In all cases, significance was considered for t-tests yielding p values below 0.05 (*), 0.01 (**) or 0.001 (***).
inflammation of the brain tissue in the neighborhood of needle trauma, visible as a bright area on the MR image and the appearance of mobile lipid peaks. Inflammation quickly disappeared within 1 week after cell implantation. The ENU gliomas showed a particularly slow growth rate (T d = 4.7 AE 1.1 weeks) and a long latency time (27 AE 4 weeks before observation of the first glioma). The latency times of the cell implantation glioma models were found to be similar, and their growth patterns, in general, were identical. However, RG2 and 9 L/LacZ models were at either end of the spectrum. In addition to their long latency time, 9 L/LacZ tumors presented long T d (4.18 AE 0.86 days) and survival time (49.3 AE 5.1 days) when compared with the other glioma models. The aggressive RG2 glioma model distinguished itself by a very rapid growth (T d = 1.5 AE 0.32 days) and a very short survival time (16.9 AE 2.27 days). Representative morphological MR images of each glioma model are shown in Fig. 1 . Rodent gliomas with distinct tumor boundaries included ENU (Fig. 1B), U87 (Fig. 1E) ( Fig. 1F) and C6 (Fig. 1G) 4 models, whereas more diffuse gliomas included GL261 (Fig. 1C) , RG2 (Fig. 1D ) and F98 (Fig. 1H ) models.
Glioma metabolic profiles
Representative localized MR spectra (PRESS) are shown in Fig. 2 , depicting metabolites in tumor and contralateral brain tissues. Estimated tumor metabolite concentrations measured by TARQUIN analysis (shown in Table 1 ) indicated that some glioma models, such as F98, RG2, C6 and GL261, showed significantly decreased levels (p < 0.05) of tCr compared with control brain tissue. It was also noted that tCr levels were significantly higher (p < 0.05) in C6 and ENU relative to F98 gliomas. The amount of NAA was found to be significantly lower (p < 0.05) in GL261, RG2 and C6 models relative to control brain tissue and the ENU model. The lipid 1.3-ppm peak was found to be significantly higher (p < 0.05) in the C6 glioma model relative to control brain tissue and all other glioma models, and significantly higher (p < 0.05) in the C6 and GL261 models relative to the ENU model. Although there was a tendency for an increase in lipid levels within tumors, this increase was found to be significant only for C6 (8.8 AE 4.1 mM) relative to controls (0.0 AE 0.0 mM). GL261 tumors presented a significant increase (p < 0.05) in the lipid methylene peak (54.5 AE 41.0 mM) relative to ENU (0.1 AE 0.2 mM). Other metabolites of note that were altered in some glioma models included GABA, Gln, Glu, Tau, Asp, Gua and MMs. GABA was found to be significantly lower (p < 0.05) in 9 L/LacZ relative to C6. It should be noted that GABA levels measured in control normal brain tissue (8.9 AE 1.9 mM; Table 1 ), in this study, are higher than those reported previously in normal rat brain tissue (39, 40) . Gln and Glu were decreased significantly (p < 0.05) in RG2 relative to CTRL, Gln was significantly higher (p < 0.05) in C6 and ENU relative to RG2, and Glu was significantly higher (p < 0.01) in ENU relative to RG2. Tau was significantly higher (p < 0.05) in GL261 relative to ENU. Asp was decreased significantly (p < 0.05) in C6 relative to CTRL, ENU and RG2. Gua was decreased significantly (p < 0.01) in F98 and U87 relative to CTRL, and increased significantly (p < 0.05) in U87, 9 L/LacZ and ENU relative to F98. MMs were elevated significantly (p < 0.01) in 9 L/LacZ and ENU relative to CTRL, and ENU showed significantly higher levels (p < 0.05) than 9 L/LacZ. Metabolites not found to change significantly in all models included tCho, Lip0.9, Lip2.0, myo-Ins, Scyllo, Ala and Glc. (see Fig. 3 for representative spectra)
DISCUSSION
Metabolic profiles of normal and glioma-bearing brain tissues were assessed by following the main rat brain metabolites (tCho, tCr, NAA and Lac) and mobile lipids using 1 H MRS in seven rodent glioma models. The growth pattern, survival, border sharpness and angiogenic ability of these models have already been characterized in detail by our group (43) . The missing piece of the puzzle was to determine whether metabolic profiles could be used to gather information on glioma malignancy.
MRS has already been reported to be an efficient technique for discrimination between brain lesions (7) and for following the response to treatments (10) . It possesses obvious advantages over other grading methods, such as contrast-enhanced MRI and biopsies. Although high blood volume is usually associated with high-grade tumors, some low-grade oligodendrogliomas can present high blood volumes, so that contrast-enhanced imaging may be of no use for the grading of these tumors (44) . It is interesting to consider MRS as an additional method for tumor grading. In particular, MRS can be used to follow two processes taken into consideration when grading, i.e. mitotic activity and necrosis. One of the brain metabolites assessed with 1 H MRS is choline (and tCho), which reflects membrane synthesis and is therefore associated with cellular proliferation in tumors (45) . tCho is found to be commonly increased in malignant gliomas (46, 47) . tCho is also linked to membrane degradation, and processes that either promote cellular proliferation or induce cell death are represented by an increased tCho peak in the MR spectrum (10, 15) . In our study, we did not observe any significant differences in the estimated tCho concentrations measured by TARQUIN analysis (see Table 1 ). tCr is a marker of the energy cycle, and its concentration is known to decrease when necrosis occurs (48) . More specifically, the degree of malignancy of the glioma is tightly correlated with the tCho/tCr ratio, and grade IV GBMs are known to possess dramatically elevated tCho/tCr ratios (49) (50) (51) . This ratio is a widely recognized marker of cellular proliferation (4,51) and thus appears to be a good candidate for tumor grading, as mitotic activity is the grading criterion that separates grade II from grade III tumors (3) [a difference of nearly 18% in the 5-year survival rate (52) ]. Some investigators have even proposed that mitotic activity is the main marker of a poor prognosis and malignancy, and that endothelial proliferation and necrosis are only secondary (53) . Estimated glioma tCr concentrations measured by TARQUIN analysis indicated that, in most glioma models, tCr was decreased, e.g. F98, RG2, GL261 and C6 models. As a result of the variation in tCr concentrations in some glioma models, metabolite ratios relative to tCr may not be an ideal parameter for comparative analysis between glioma models or tumor grades.
Another brain metabolite of interest is NAA, which is a marker of neuronal integrity (15) and possesses several functions, such as the regulation of neuronal protein synthesis and the metabolism of neurotransmitters. When neuronal death occurs, the NAA peak decreases (54) . A common observation in malignant human brain tumors is that NAA is present at low concentrations (46, 47, 55) . It should be noted that there is a lipid/MM peak at 2.05 ppm detected in brain tumor spectra which may compromise the signal from NAA at 2.00 ppm (19, 56) . This is particularly apparent in metastatic brain tumors because of the relatively long T 2 value of the 2.05-ppm Lip/MM peak, thought to be contributed by mucus glycoproteins; this could be used to differentiate metastatic brain tumors from GBM (56) . The estimated NAA concentrations measured from TARQUIN analysis indicated significantly decreased NAA levels only in GL261, C6 and RG2 glioma models relative to control brain tissue and the ENU model. Ala, alanine; Asp, aspartate; ENU, ethyl-nitrosourea; GABA, g-aminobutyric acid; Glc, glucose; Gln, glutamine; Glu, glutamate; Gua, guanosine; myo-Ins, myo-inositol; Lac, lactate; MMs, macromolecules; NAA, N-acetylaspartate; Scyllo, scyllo-inositol; Tau, taurine; tCho, total choline; tCr, total creatine. Sample numbers are: F98 (n = 4), U87 (n = 5), RG2 (n = 5), GL261 (n = 5), C6 (n = 5) and CTRL (intracerebral injection of astrocytes; n = 4). Tumor metabolite concentrations were obtained in each glioma model when the maximum tumor dimensions had been reached at days 17-21 for C6, days 14-26 for RG2, days 15-35 for U87, days 36-47 for 9 L/lacZ, days 18-26 for F98 and days 23-35 for GL261. The rats bearing ENU-induced gliomas were assessed at 33-39 weeks of age. Statistics were obtained using a two-tailed unpaired Student's t-test. The assignment of metabolites and subsequent concentration measurements were based on the published literature: NAA was assigned at 2.02 ppm, tCr at 3.03 ppm, tCho at 3.22 ppm, Lac at 1.32 ppm, Ala at 1.47 ppm, Gln at 2.12 ppm, Glu at 2.35 ppm, Asp at 2.79 ppm, Tau at 3.42 ppm and myo-Ins at 3.53 ppm (40) . Mobile lipid peaks are associated with the fatty acyl proton groups CH 2 (predominantly saturated methylene hydrogens; Lip1.3 = Lip1.3a + Lip1.3b) and CH 3 (methyl hydrogens; Lip0.9) (41). For some metabolites, concentrations were combined to reflect total levels {e. Mobile lipids (observed through their saturated methylene and methyl groups) are also useful to monitor in many pathologies, such as brain tumors and ischemic injuries, as they reflect necrosis (19) , an important grading criterion (3), and GBMs are known to possess high levels of mobile lipids (4, 19, 57) . NMRvisible mobile lipids (lipid/MM signals observed at approximately 1.3 and 0.9 ppm) appear to be an inherent feature of brain tumors, and are considered to be an important factor in the grading of in vivo 1 H MRS astrocytoma spectra (58) (59) (60) (61) . Mobile lipids originate from membrane phospholipids that are degraded during membrane breakdown and necrosis (6, 62) . Tumor malignancy may be linked to the elevated presence of lipids in the tissue, as high-grade tumors usually present pronounced necrosis (49, 50, 63) as a result of their increased nutrient and oxygen needs and their inadequate vascularization, inducing hypoxia. There are also some reports that have examined the accumulation of lipids as a marker for growth arrest, the early detection of tumor eradication and the detection of apoptosis following anti-cancer therapy (64, 65 also been found to generally increase with malignancy (58, 59) , although no direct correlations have been made with tumor grading (59, 66) . Depending on the pulsing conditions for MRS, the Lac peak(s) at approximately 1.3 ppm (doublet at 1.25 and 1.33 ppm) may also contribute to the lipid 1.3-ppm peak, which may affect the detection of mobile lipids (62) . In our study, Lac was found to be elevated significantly (p < 0.05) in the GL261 model relative to controls and the ENU model.
It is commonly known that gliomas are characterized by elevated tCho/tCr and lipid/tCr ratios, and by decreased NAA levels (15, 46, 47) . As tCr was found to change in our study, it is not a good reference to use when comparing other metabolites. As both NAA and tCr are known to decrease during tumor progression (48) , ratio variations could be relatively insensitive or even remain constant despite changes in the individual metabolite concentrations. High-grade gliomas are also known to present more dramatic changes than low-grade gliomas (51) .
All the glioma implantation models studied in this project (C6, 9 L/LacZ, F98, RG2, U87 and GL261) are considered to be good models of human-like gliomas (grades III-IV), and numerous studies have used them (67) . If this is the case, one would expect them to exhibit similar spectra and metabolic profiles. Some investigators have shown that, by using the same cell line, tumors with different MRS characteristics can be generated in vivo (68) . It has been shown that metabolic profiles detected by 1 H MRS can be used to distinguish between two distinct human GBM phenotypes in immunodeficient rats that gradually changed following serial passages, from a highly infiltrative, nonangiogenic, low-generation (LG) tumor to a high-generation (HG) tumor with extensive angiogenesis and necrosis, with the LG tumor having significantly higher levels of Cho and Lac than the HG tumor (68) . The ENU-induced model has been reported previously to be low grade (21) and, in our study, seems to have many metabolite levels (except for MMs) that are similar to those of the control. Although a previous 1 H MRS study performed on F98 rat gliomas found an increase in Cho, myo-Ins, lipids and Lac, an absence of signals from NAA and a loss of tCr (69) , these were only detected as trends in our study, and not found to differ significantly from controls.
To our knowledge, this is the first study to compare simultaneously the metabolic profiles in seven rodent glioma models using MRS, and to correlate these findings with MRI and histology. The similar metabolic profiles expected in the seven rodent glioma models studied did not materialize, and we were able to show that some of the glioma models possessed different metabolic fingerprints. Slow-growing ENU and 9 L/LacZ gliomas showed only slightly decreased tCr levels relative to controls, whereas the aggressive RG2, C6 and GL261 tumors presented dramatically decreased tCr levels, reflected in their high tumor growth activity. The GL261 model showed the most metabolite alterations relative to all other models. When considering metabolites other than NAA, tCr, lipids and Lac, C6 was found to differ from RG2 when assessing Gln and Asp levels.
In this study, we measured the estimated metabolite concentrations. However, this determination must take into consideration many different factors, such as the homogeneity of the field (32), quality of water suppression, receiver gain of the magnet, T 1 and T 2 relaxation of the metabolites of interest [which can vary in pathological states (32, 66) ] and the cellular dilution of metabolites caused by the presence of necrotic regions (15, 66) . High-grade tumors are quite heterogeneous, consisting of necrotic regions, cystic regions and areas of viable and hypoxic tumor cells (70) , and therefore the absolute concentrations of metabolites, lipids and MMs are highly variable because of partial volume effects (56) . As the absolute concentrations are dependent on tissue cellularity, which decreases when necrosis occurs (15) , some investigators have recommended that relative ratios should be used in the case of highly necrotic tumors (15) . The assessment of relative ratios may also be easier to implement in clinical settings to ensure that MRS results can be compared between laboratories. It should also be noted that, for some metabolites, such as GABA, TARQUIN may have some problems in estimating the concentrations, as the GABA levels in this study were higher than those reported previously (39, 40) .
It can also be proposed that MRSI should be used to provide more detailed spatial information on each of the glioma models, or that two-dimensional spectroscopic methods should be employed to elucidate the chemical structures, particularly when there are overlapping signals from different metabolites. Some advantages of MRS over MRSI are that the former provides a stronger signal in a shorter time frame, and the homogeneity of the magnetic field can be carefully adjusted over a small volume of interest free of any tissue interfaces. However, it has been demonstrated that 1 H MRSI may be a potential method for the preoperative grading of grade II and III gliomas, where significantly lower Cho levels and higher total NAA levels are found in grade II tumors relative to grade III tumors (71) . In addition, one can correlate more thoroughly data obtained from morphological T 2 -weighted images, and/or diffusion-weighted images, with MR spectra. Another potential use for MRS/MRSI would be to establish a more accurate tumor margin, which is often underestimated with T 2 -weighted imaging and/or contrast-enhanced MRI, and contributes to the high recurrence rate of malignant gliomas.
CONCLUSION
MRS monitors processes that are essential during tumor growth, such as the mitotic activity of glioma cells (tCho/tCr) and necrosis (elevated lipids and decreased tCr). We have shown in this study that MRS can distinguish between different metabolic profiles in a number of rodent glioma models that are often considered to be similar. For instance, if a decrease in NAA and/or tCr is the metabolic criterion to be used, glioma models GL261, RG2 or C6 should be considered as malignant models (all with grade IV characteristics). However, if the lipid or Lac profile is the metabolic criterion of assessment, the C6 or GL261 model, respectively, should be considered, based on our results. Some of the glioma models, such as U87, RG2 and 9 L/LacZ, show large standard deviations in some metabolite concentrations, which is a reflection of tumor growth variations in these models. The ENU model was found to be most similar to controls, and different from C6, GL261, 9 L/LacZ and RG2 models, and therefore should not be used as a malignant model. The GL261 model seemed to be most different from all of the others and, of all the models assessed in this study, it is perhaps the most malignant in nature.
